CorEvitas PsA Registry (1000+ pts) Analysis of biologics prescription according to disease domains No real surprise to see that IL-17i were prescribed more frequently in pts w/ PsO BSA>10% at BL Overall first line TNFi 40% > IL-17i 14% POS0309 @RheumNow #EULAR2022 https://t.co/dkLxl8d6ug

The two forms of Axial PsA - classical (Axial SpA like) and alternative. Plenary session today #EULAR2022 by Prof. Philip Helliwell. I will be discussing this further in my vlog @RheumNow https://t.co/hxAhgMhHlJ

Kristensen et al. IL23i Risankizumab improves fatigue, health related quality of life, work productivity in PsA. @RheumNow #EULAR2022 POS1042 https://t.co/fnoCZCpwNM

Nash @drpnash et al. IL23i guselkumab improves pain in PsA. Good to see as it is a really important PRO, but there is still significant work to do, week 24 - 60% had <50% and 37% had <20% improvement in pain @RheumNow #EULAR2022 POS1044 https://t.co/H92r4leslT

Mulder et al. COMPLETE-PsA trial. MTX+LEF vs MTX mono. 78 patient RCT. LEF 20mg, MTX 25mg. MTX+LEF more effective (MDA 59% vs 32%) but less well tolerated (3 SAE vs 0; N+V, diarrhoea. No mention of LFTs). @RheumNow #EULAR2022 POS0078 https://t.co/2D84EFmabc

So what diet to follow with autoimmunity in mind? So many, all with different instructions. Let’s concentrate on where they agree: yes to fruits & vegetables no to emulsifiers & processed foods #EULAR2022 @RheumNow https://t.co/I9abweQOyZ

Mease et al. IL23i guselkumab on axial outcomes in PsA at 2 years in DISCOVER-2. Guselkumab improves BASDAI, mBASDAI, spinal pain, ASDAS to week 100. Still trying to get my head around this seeming to work for PsA spinal disease but not axSpA @RheumNow #EULAR2022 POS1037 https://t.co/LZgXEl6Ohl

Does diet drive IL-23 in IBD and PsA? Perhaps if you have the right baseline risk. The science is evolving quickly Stronger rationale that diet may be really important in some patients #EULAR2022 #IL23 @RheumNow https://t.co/hV54PvfOXV